van Leusden H A, Dogterom A A
Department of Gynaecology, De Malberg-EG Hospital, Arnhem, The Netherlands.
Gynecol Endocrinol. 1988 Mar;2(1):45-51. doi: 10.3109/09513598809029338.
Ten women with intramural leiomyomas were treated with the microencapsulated GnRH analogue Decapeptyl for 24 weeks. Four (4) mg Decapeptyl was injected, starting on day 21 of the menstrual cycle, and injections were repeated every 4 weeks for a total of 24 weeks. All patients showed a marked reduction in uterine size: before treatment it measured 284 +/- 57 cm3, after 8 weeks 122 +/- 33 cm3, and after 24 weeks 89 +/- 14 cm3. LH and estradiol decreased significantly; FSH decreased but not significantly; prolactin remained almost unaltered. Serum calcium, phosphate, alkaline phosphatase and osteocalcin increased, but, since calcium excretion (and hydroxyproline excretion) remained unaltered, these changes were considered to reflect increased bone turnover rather than bone loss. From these data it is concluded that Decapeptyl is very effective in reducing uterine fibroids, that treatment can be shorter than 6 months and that measurable bone loss did not occur.
十名患有壁间平滑肌瘤的女性接受了微囊化促性腺激素释放激素类似物(GnRHa)曲普瑞林治疗24周。从月经周期的第21天开始,注射4毫克曲普瑞林,每4周重复注射一次,共注射24周。所有患者的子宫大小均显著缩小:治疗前子宫体积为284±57立方厘米,8周后为122±33立方厘米,24周后为89±14立方厘米。促黄体生成素(LH)和雌二醇显著下降;促卵泡生成素(FSH)有所下降但不显著;催乳素几乎没有变化。血清钙、磷、碱性磷酸酶和骨钙素升高,但由于钙排泄(以及羟脯氨酸排泄)保持不变,这些变化被认为反映了骨转换增加而非骨质流失。从这些数据可以得出结论,曲普瑞林在缩小子宫肌瘤方面非常有效,治疗时间可以短于6个月,且未发生可测量的骨质流失。